Over the past 12 months, 8 insiders at Edgewise Therapeutics, Inc. filed 21 open-market SEC Form 4 transactions on EWTX: 1 purchase worth $199K and 20 sales worth $18.4M. Insiders have been net sellers over this period. The most recent filing was on Jul 1, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 26 | Alan J RussellChief Scientific Officer | SELL | 130.4K | $39.41 | $5.1M |
| May 5, 26 | Joanne M. DonovanCMO | SELL | 50.0K | $38.57 | $1.9M |
| May 4, 26 | Joanne M. DonovanCMO | SELL | 5.2K | $31.29 | $164K |
| Mar 31, 26 | Joanne M. DonovanCMO | SELL | 21.3K | $32.12 | $685K |
| Mar 27, 26 | Joanne M. DonovanCMO | SELL | 9.6K | $30.98 | $298K |
| Jan 21, 26 | Badreddin EdrisDirector | SELL | 66.5K | $29.44 | $2.0M |
| Nov 12, 25 | Alan J RussellChief Scientific Officer | SELL | 100.0K | $21.12 | $2.1M |
| Nov 11, 25 | Jonathan C FoxDirector | BUY | 10.7K | $18.64 | $199K |
| Aug 26, 25 | Alan J RussellChief Scientific Officer | SELL | 100.0K | $14.60 | $1.5M |
| Aug 12, 25 | R Michael CarruthersChief Financial Officer | SELL | 1.4K | $13.39 | $19K |
| Aug 12, 25 | Behrad DerakhshanChief Business Officer | SELL | 2.5K | $13.39 | $33K |
| Aug 12, 25 | Joanne M. DonovanCMO | SELL | 2.9K | $13.39 | $38K |
| Aug 12, 25 | Kevin KochPresident and CEO | SELL | 8.0K | $13.39 | $107K |
| Aug 12, 25 | John R MooreGeneral Counsel | SELL | 2.1K | $13.39 | $28K |
| Aug 12, 25 | Alan J RussellChief Scientific Officer | SELL | 1.9K | $13.39 | $26K |
| May 2, 25 | R Michael CarruthersChief Financial Officer | SELL | 1.3K | $16.45 | $22K |
| May 2, 25 | Behrad DerakhshanChief Business Officer | SELL | 1.7K | $16.45 | $28K |
| May 2, 25 | Joanne M. DonovanCMO | SELL | 5.2K | $16.45 | $85K |
| May 2, 25 | Kevin KochPresident and CEO | SELL | 4.3K | $16.45 | $70K |
| May 2, 25 | John R MooreGeneral Counsel | SELL | 1.9K | $16.45 | $32K |
| May 2, 25 | Alan J RussellChief Scientific Officer | SELL | 1.6K | $16.45 | $26K |
| Apr 3, 25 | Orbimed Genesis Gp LlcDirector,TenPercentOwner | BUY | 372.6K | $20.13 | $7.5M |
| Apr 3, 25 | Peter A. ThompsonDirector,TenPercentOwner | BUY | 372.6K | $20.13 | $7.5M |
| Mar 7, 25 | Kevin KochPresident and CEO | SELL | 100 | $30.00 | $3K |
| Mar 7, 25 | Alan J RussellChief Scientific Officer | SELL | 200 | $30.02 | $6K |
| Feb 6, 25 | Kevin KochPresident and CEO | SELL | 900 | $31.13 | $28K |
| Feb 6, 25 | Alan J RussellChief Scientific Officer | SELL | 1.2K | $30.13 | $36K |
| Feb 5, 25 | Behrad DerakhshanChief Business Officer | SELL | 10.0K | $30.03 | $300K |
| Feb 5, 25 | Kevin KochPresident and CEO | SELL | 8.6K | $30.03 | $259K |
| Feb 5, 25 | Alan J RussellChief Scientific Officer | SELL | 8.0K | $30.02 | $241K |
| Jan 28, 25 | Joanne M. DonovanCMO | SELL | 25.0K | $27.63 | $691K |
| Dec 30, 24 | Alan J RussellChief Scientific Officer | SELL | 100.0K | $27.37 | $2.7M |
| Dec 24, 24 | Marc SemigranChief Development Officer | SELL | 28.0K | $30.08 | $830K |
| Sep 23, 24 | John R MooreGeneral Counsel | SELL | 20.9K | $27.63 | $578K |
| Sep 20, 24 | R Michael CarruthersChief Financial Officer | SELL | 50.0K | $28.59 | $1.4M |
| Sep 20, 24 | Behrad DerakhshanChief Business Officer | SELL | 42.1K | $29.03 | $1.2M |
| Sep 20, 24 | Joanne M. DonovanCMO | SELL | 7.2K | $28.29 | $203K |
| Sep 20, 24 | John R MooreGeneral Counsel | SELL | 50.0K | $28.37 | $1.4M |
| Sep 20, 24 | Alan J RussellChief Scientific Officer | SELL | 74.2K | $29.51 | $2.1M |
| May 2, 24 | R Michael CarruthersChief Financial Officer | SELL | 2.2K | $18.91 | $41K |
| May 2, 24 | Behrad DerakhshanChief Business Officer | SELL | 1.7K | $18.91 | $32K |
| May 2, 24 | Joanne M. DonovanCMO | SELL | 3.7K | $18.91 | $70K |
| May 2, 24 | Kevin KochPresident and CEO | SELL | 3.2K | $18.91 | $60K |
| May 2, 24 | John R MooreGeneral Counsel | SELL | 2.0K | $18.91 | $37K |
| May 2, 24 | Alan J RussellChief Scientific Officer | SELL | 1.6K | $18.91 | $30K |
| Feb 9, 24 | Behrad DerakhshanChief Business Officer | SELL | 4.8K | $20.04 | $96K |
| Feb 9, 24 | John R MooreGeneral Counsel | SELL | 8.0K | $20.01 | $161K |
| Feb 8, 24 | Behrad DerakhshanChief Business Officer | SELL | 4.6K | $20.01 | $92K |
| Feb 8, 24 | John R MooreGeneral Counsel | SELL | 3.8K | $20.01 | $76K |
| Feb 7, 24 | Behrad DerakhshanChief Business Officer | SELL | 600 | $20.00 | $12K |
Over the past 12 months, insiders at Edgewise Therapeutics, Inc. filed 1 open-market purchase worth $199K and 20 sales worth $18.4M on EWTX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 1, 26.
The largest recent open-market EWTX insider purchase in our data was $7.5M by Orbimed Genesis Gp Llc, Director,TenPercentOwner, filed on Apr 3, 25.
8 different insiders at Edgewise Therapeutics, Inc. filed open-market SEC Form 4 transactions on EWTX over the last 12 months.
InsiderTape plots every EWTX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Edgewise Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →